menu
    • menu

    Company profile for Alchem International Private Ltd

    NEW Drugs in Dev: 1
    Key Product, Service and Excipients-PSE
    News
    Prof. Dr. Serhat Ünal Tells: Things to Consider in the Influenza & COVID Spiral

    17 Dec 2022

    // WINALLY

    Sales Focus Expands Sales Outsourcing Services into the Healthcare Industry

    01 Nov 2022

    // PR NEWSWIRE

    AlChem Life USA and Stevenson Advocacy LLC donate $1.35 million worth

    14 Oct 2021

    // PHILLYVOICE

    DATA COMPILATION
    #PharmaFlow

    Alchem

    Contact Supplier

    Website

    CPhI China

    Booth #E1D32

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Related CompaniesRelated Companies

    About

    With over 85 years of research-driven innovation, Alchem International manufactures high-quality plant-based active ingredients for the pharmaceutical, cosmetic, and nutraceutical industries. Our expertise spans extraction, purification, production, and customer service, making us a trusted long-term partner. We operate three cGMP-certified facilities in India, audited by the US FDA, EDQM, and COFEPRIS. Most products are supported by DMFs, CEPs (COS), and Written Confirmations, with dossiers filed in over 30 countries. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alchem International Private Ltdindia-flag Flag
    Country
    Country
    India
    Address
    Address
    201, Empire Plaza, Mehrauli - Gurgaon Road, Sultanpur, New Delhi-110 030
    Telephone
    Telephone
    +91 1126809882
    Client Email
    Email
    contact@alcheminternational.com
    Client Website
    Website
    http://www.alcheminternational.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alchem-international-pvt-ltd/
    youtube
    YouTube
    https://www.youtube.com/@AlchemLifeIndia/videos
    Twitter
    Twitter
    Contact Info
    Others

    Email ID:

    contact@alcheminternational.com

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI China

    Booth #E1D32

    envelop Contact Supplier

    CPhI China

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 2354

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    read-more

    ReelPharmaT-MAX™ 3-in-1 Formula: For Next-Gen E-LiquidsT-MAX™ 3-in-1 Formula: For Next-Gen E-Liquids

    T-MAX™ 3-in-1 Formula: For Next-Gen E-Liquids
    T-MAX™ 3-in-1 Formula: For Next-Gen E-Liquids

    reelT-MAX™ 3-in-1 Formula: For Next-Gen E-Liquids

    T-MAX™ by Alchem NicSelect™ — the patented nicotine formulation redefining satisfaction in flavour-restricted markets — is now available royalty-free to key customers. Experience the 3-in-1 nicotine satisfaction with speed, power, and throat hit, fully GMP-compliant and EU TPD-ready.

    Impressions: 1834

    read-more

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/alchem-international-private-ltd-party-content-87804.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    WHO GMP Certificate 2023-2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/alchem-international-private-ltd-party-content-19254.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    PharmaCompass is introducing a new regulatory update that tracks developments in Certificates of Suitability to the Monographs of the European Pharmacopoeia, referred to as CEPs. These certificates are a critical regulatory instrument in the global pharmaceutical supply chain.Also known as a Certification of Suitability (COS), CEPs are issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), with or without inspection of the manufacturing site. A CEP must be renewed every five years from its original issue date to remain valid, regardless of any revisions made during the interim period. However, a CEP does not replace Good Manufacturing Practice certification.CEPs are recognized as a trusted reference for API quality, thereby simplifying global registration strategies. Apart from Europe, the CEP system is widely used by many regulatory authorities, including those in Canada, Australia, Brazil, Singapore and South Africa. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)CEP 2.0 enhances regulatory clarity, brings efficiency, global interoperability There are several types of CEPs, depending on the nature of the substance and evaluation. The most common type is the Chemical CEP, which confirms that a chemically synthesized API meets standards for purity and impurity control. Then there are Herbal CEPs for herbal substances and preparations.Another key category is the TSE CEP, which addresses risks associated with transmissible spongiform encephalopathies in animal-derived materials. In addition, there are Combined CEPs that may cover multiple aspects, such as chemical quality, TSE risk, and sterility. However, biological products such as vaccines and blood products fall outside the scope of the CEP framework.In 2023, the CEP system underwent a major transformation with the introduction of CEP 2.0, which marks a shift from a largely document-based system to a more structured, transparent, and digitally aligned model. This makes it easier for companies to manage compliance while improving trust among global regulators.While increasing data and compliance requirements for API manufacturers, CEP 2.0 enables better regulatory clarity, streamlined dossier integration, and stronger global acceptance. Overall, CEP 2.0 is designed to enhance regulatory clarity while making the system more efficient and globally interoperable. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Indian firms issued maximum CEPs; Sun Pharma and its subsidiaries, Jubilant Biosys top listIndia topped the charts for CEPs issued, both in terms of new CEPs and revisions in the first quarter (Q1) of 2026. Indian companies were issued 81 new CEPs in Q1 2026 (as against 40 in Q1 2025) and 203 revisions (as against 129 in Q1 2025). In comparison, Chinese companies were issued 42 new CEPs in Q1 2026 (against 25 in Q1 2025) and 53 revisions (against 67 in Q1 2025). Italy came a distant third, followed by Germany and Spain.India’s Sun Pharmaceuticals and its subsidiaries topped the list of companies with the maximum number of CEPs issued— while no new CEP was issued, 27 CEPs were revised in Q1 2026. At second place was Jubilant Biosys — 21 CEPs were revised in Q1 2026.In terms of products, the maximum CEPs were issued for amlodipine besylate (a calcium channel blocker used for treating hypertension), followed by sitagliptin phosphate (a type 2 diabetes medicine) and pregabalin (a drug used to treat neuropathic pain, fibromyalgia, seizures, and generalized anxiety disorder). Both amlodipine besylate and sitagliptin phosphate had not been issued new CEPs or revisions in Q1 2025. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)EDQM introduces new guidelines to accelerate CEP assessments The EDQM charges fees for various services related to CEPs that depend on the type of request or regulatory activity involved. In general, fees apply to handling CEP applications, revisions or renewals and for offering technical advice (where applicants seek scientific or regulatory guidance).In March 2026, the EDQM introduced two new guidelines aimed at accelerating CEP assessments. The first is a reliance-based assessment pathway, which allows regulators to leverage prior approvals from trusted authorities, such as those in the EU, UK, Australia, Canada, and the WHO pre-qualification program. The second is a fast-track assessment route designed to expedite reviews in situations such as medicine shortages and to support initiatives like the EU Critical Medicines Act.Timelines have been significantly compressed under these new pathways. Initial evaluations are completed within 46 working days, compared to up to 115 days under the standard procedure. Applicants are given 30 calendar days to respond to queries, after which regulators complete the final assessment within 23 working days.Another important regulatory update relates to electronic submissions. From April 1, 2026, the EDQM will reject non-compliant CEP applications at the point of submission. All applications must include a validated electronic Common Technical Document (eCTD) dossier along with a proper validation report, submitted in line with the updated Common European Submission Portal (CESP) guidelines. Taken together, these developments signal a more rigorous yet efficient CEP ecosystem. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Our viewThe shift to CEP 2.0 signals a move toward greater transparency, digitalization, and global regulatory alignment. Though enhanced disclosure and stricter e-submission requirements may increase the compliance burden, especially for smaller manufacturers, the long-term gains are expected to be significant. Going forward, companies that invest in data quality and regulatory readiness stand to gain from these changes.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1269

    https://www.pharmacompass.com/radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued

    #PharmaFlow by PHARMACOMPASS
    09 Apr 2026
    Share Share
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 15984

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Prof. Dr. Serhat Ünal Tells: Things to Consider in the Influenza & COVID Spiral
    Prof. Dr. Serhat Ünal Tells: Things to Consider in the Influenza & COVID Spiral

    17 Dec 2022

    // WINALLY

    https://www.pharmacompass.com/pdf/news/prof-dr-serhat-nal-tells-things-to-consider-in-the-influenza-covid-spiral-55169.pdf

    WINALLY
    17 Dec 2022
    Share Share
    Sales Focus Expands Sales Outsourcing Services into the Healthcare Industry
    Sales Focus Expands Sales Outsourcing Services into the Healthcare Industry

    01 Nov 2022

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sales-focus-inc-expands-sales-outsourcing-services-into-the-healthcare-industry-with-six-new-clients-301664530.html

    PR NEWSWIRE
    01 Nov 2022
    Share Share
    AlChem Life USA and Stevenson Advocacy LLC donate $1.35 million worth
    AlChem Life USA and Stevenson Advocacy LLC donate $1.35 million worth

    14 Oct 2021

    // PHILLYVOICE

    https://www.phillyvoice.com/alchem-life-usa-and-stevenson-advocacy-llc-donation-immunity-boosting-supplement-0599962/

    PHILLYVOICE
    14 Oct 2021
    Share Share
    AIIMS Patna confirms efficacy of AlchemLife’s Phytorelief to combat
    AIIMS Patna confirms efficacy of AlchemLife’s Phytorelief to combat

    10 Jun 2021

    // ECONOMICTIMES

    https://health.economictimes.indiatimes.com/news/pharma/aiims-patna-confirms-efficacy-of-alchemlifes-phytorelief-to-combat-moderate-cases-of-covid-19/83401825

    ECONOMICTIMES
    10 Jun 2021
    Share Share
    University Researcher Analyzes Herbal Supplement's Potential Against COVID
    University Researcher Analyzes Herbal Supplement's Potential Against COVID

    23 Feb 2021

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/university-researcher-analyzes-herbal-supplements-potential-against-covid-19-301233869.html

    PR NEWSWIRE
    23 Feb 2021
    Share Share
    Alchemlife's Phytorelief-CC being used immunity booster
    Alchemlife's Phytorelief-CC being used immunity booster

    08 Dec 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/in/news-releases/alchemlife-s-phytorelief-cc-being-used-in-eminent-indian-hospitals-as-an-immunity-booster-845237627.html

    PR NEWSWIRE
    08 Dec 2020
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Alchem International Private Ltd full-view
    Extracts from Fresh & Dried Plants
    full-view

    REF. STANDARDS & IMPURITIES

    Check the ref. standards & impurities from this company

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Alchem International Ltd and get a quotation

    Alchem International Ltd is a supplier offers 56 products (APIs, Excipients or Intermediates).

    Find Digoxin bulk with DMF, CEP, JDMF, WC offered by Alchem International Ltd

    Find Atropine Sulfate bulk with DMF, CEP, WC offered by Alchem International Ltd

    Find Colchicine bulk with DMF, CEP, WC offered by Alchem International Ltd

    Find Hyoscine Butyl Bromide bulk with CEP, JDMF, WC offered by Alchem International Ltd

    Find Nicotine bulk with DMF, CEP, WC offered by Alchem International Ltd

    Find Calcium Sennoside bulk with JDMF, WC offered by Alchem International Ltd

    Find Enoxolone bulk with CEP, WC offered by Alchem International Ltd

    Find Methscopolamine Bromide bulk with DMF, WC offered by Alchem International Ltd

    Find Nicotine bulk with CEP, WC offered by Alchem International Ltd

    Find Scopolamine bulk with DMF, WC offered by Alchem International Ltd

    Find Scopolamine Hydrobromide bulk with DMF, WC offered by Alchem International Ltd

    Find Sennosides bulk with JDMF, WC offered by Alchem International Ltd

    Find Thiocolchicoside bulk with CEP, WC offered by Alchem International Ltd

    Find 10-Deacetylbaccatin- III bulk with DMF offered by Alchem International Ltd

    Find Ammonium Glycyrrhizinate bulk with WC offered by Alchem International Ltd

    Find Atropine Sulfate bulk with WC offered by Alchem International Ltd

    Find Calcium Sennoside bulk with JDMF offered by Alchem International Ltd

    Find Centella Asiatica Triterpenes bulk with WC offered by Alchem International Ltd

    Find Cimetropium Bromide bulk with WC offered by Alchem International Ltd

    Find Digoxin bulk with CEP offered by Alchem International Ltd

    Find Docetaxel bulk with WC offered by Alchem International Ltd

    Find Enoxolone bulk with WC offered by Alchem International Ltd

    Find Homatropine Hydrobromide bulk with WC offered by Alchem International Ltd

    Find Homatropine Methylbromide bulk with WC offered by Alchem International Ltd

    Find Hyoscine Butyl Bromide bulk with WC offered by Alchem International Ltd

    Find Hyoscyamine Sulfate bulk with WC offered by Alchem International Ltd

    Find Nicotine bulk with WC offered by Alchem International Ltd

    Find Paclitaxel bulk with WC offered by Alchem International Ltd

    Find Quinine Hydrochloride bulk with WC offered by Alchem International Ltd

    Find Quinine Sulfate bulk with WC offered by Alchem International Ltd

    Find Reserpine bulk with WC offered by Alchem International Ltd

    Find Scopolamine Hydrobromide bulk with WC offered by Alchem International Ltd

    Find Sennosides bulk with JDMF offered by Alchem International Ltd

    Find Thiocolchicoside bulk with WC offered by Alchem International Ltd

    Find Vincamine bulk with WC offered by Alchem International Ltd

    Find Vinpocetine bulk with WC offered by Alchem International Ltd

    Find Yohimbine Hydrochloride bulk with WC offered by Alchem International Ltd

    Find 18 Beta-Glycyrrhetinic Acid bulk offered by Alchem International Ltd

    Find Aescin bulk offered by Alchem International Ltd

    Find Andrographolide bulk offered by Alchem International Ltd

    Find Atropine bulk offered by Alchem International Ltd

    Find Belladonna Leaf Extract bulk offered by Alchem International Ltd

    Find Boswellia Serrata bulk offered by Alchem International Ltd

    Find Cimetropium Bromide bulk offered by Alchem International Ltd

    Find Coleus Forskohlii Extract bulk offered by Alchem International Ltd

    Find Dipotassium Glycyrrhizinate bulk offered by Alchem International Ltd

    Find Glabridin bulk offered by Alchem International Ltd

    Find Glycrrhizin bulk offered by Alchem International Ltd

    Find Horse Chestnut Extract bulk offered by Alchem International Ltd

    Find Nicotine Benzoate bulk offered by Alchem International Ltd

    Find Nicotine Lactate bulk offered by Alchem International Ltd

    Find Nicotine Salicylate bulk offered by Alchem International Ltd

    Find Pygeum Extract bulk offered by Alchem International Ltd

    Find Ruscogenin bulk offered by Alchem International Ltd

    Find Scopine Hydrochloride bulk offered by Alchem International Ltd

    Find Valerian Officinalis bulk offered by Alchem International Ltd

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search